227 related articles for article (PubMed ID: 37047778)
41. Hierarchy of protein tyrosine kinases in interleukin-2 (IL-2) signaling: activation of syk depends on Jak3; however, neither Syk nor Lck is required for IL-2-mediated STAT activation.
Zhou YJ; Magnuson KS; Cheng TP; Gadina M; Frucht DM; Galon J; Candotti F; Geahlen RL; Changelian PS; O'Shea JJ
Mol Cell Biol; 2000 Jun; 20(12):4371-80. PubMed ID: 10825200
[TBL] [Abstract][Full Text] [Related]
42. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.
Waldmann TA
Mol Cell Endocrinol; 2017 Aug; 451():66-70. PubMed ID: 28214593
[TBL] [Abstract][Full Text] [Related]
43. Cell type-specific roles of Jak3 in IL-2-induced proliferative signal transduction.
Fujii H
Biochem Biophys Res Commun; 2007 Mar; 354(3):825-9. PubMed ID: 17266928
[TBL] [Abstract][Full Text] [Related]
44. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains.
Chen M; Cheng A; Candotti F; Zhou YJ; Hymel A; Fasth A; Notarangelo LD; O'Shea JJ
Mol Cell Biol; 2000 Feb; 20(3):947-56. PubMed ID: 10629052
[TBL] [Abstract][Full Text] [Related]
45. Regulation of JAK3 expression and activation in human B cells and B cell malignancies.
Tortolani PJ; Lal BK; Riva A; Johnston JA; Chen YQ; Reaman GH; Beckwith M; Longo D; Ortaldo JR; Bhatia K; McGrath I; Kehrl J; Tuscano J; McVicar DW; O'Shea JJ
J Immunol; 1995 Dec; 155(11):5220-6. PubMed ID: 7594533
[TBL] [Abstract][Full Text] [Related]
46. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
[TBL] [Abstract][Full Text] [Related]
47. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
[TBL] [Abstract][Full Text] [Related]
48. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits.
Miyazaki T; Kawahara A; Fujii H; Nakagawa Y; Minami Y; Liu ZJ; Oishi I; Silvennoinen O; Witthuhn BA; Ihle JN
Science; 1994 Nov; 266(5187):1045-7. PubMed ID: 7973659
[TBL] [Abstract][Full Text] [Related]
49. Differential role of Janus family kinases (JAKs) in interferon-gamma-induced lung epithelial ICAM-1 expression: involving protein interactions between JAKs, phospholipase Cgamma, c-Src, and STAT1.
Chang YJ; Holtzman MJ; Chen CC
Mol Pharmacol; 2004 Mar; 65(3):589-98. PubMed ID: 14978237
[TBL] [Abstract][Full Text] [Related]
50. Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling.
Rutherford C; Speirs C; Williams JJ; Ewart MA; Mancini SJ; Hawley SA; Delles C; Viollet B; Costa-Pereira AP; Baillie GS; Salt IP; Palmer TM
Sci Signal; 2016 Nov; 9(453):ra109. PubMed ID: 27919027
[TBL] [Abstract][Full Text] [Related]
51. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
Virtanen A; Palmroth M; Liukkonen S; Kurttila A; Haikarainen T; Isomäki P; Silvennoinen O
Arthritis Rheumatol; 2023 Nov; 75(11):2054-2061. PubMed ID: 37134144
[TBL] [Abstract][Full Text] [Related]
52. Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.
Sim SH; Kim S; Kim TM; Jeon YK; Nam SJ; Ahn YO; Keam B; Park HH; Kim DW; Kim CW; Heo DS
Am J Pathol; 2017 May; 187(5):980-986. PubMed ID: 28284718
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of Janus kinases by tyrosine phosphorylation inhibitor, Tyrphostin AG-490.
Rashid S; Bibi N; Parveen Z; Shafique S
J Biomol Struct Dyn; 2015; 33(11):2368-79. PubMed ID: 26017266
[TBL] [Abstract][Full Text] [Related]
54. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
[TBL] [Abstract][Full Text] [Related]
55. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.
Jeong EG; Kim MS; Nam HK; Min CK; Lee S; Chung YJ; Yoo NJ; Lee SH
Clin Cancer Res; 2008 Jun; 14(12):3716-21. PubMed ID: 18559588
[TBL] [Abstract][Full Text] [Related]
56. Janus Kinase 3 phosphorylation and the JAK/STAT pathway are positively modulated by follicle-stimulating hormone (FSH) in bovine granulosa cells.
Zareifard A; Beaudry F; Ndiaye K
BMC Mol Cell Biol; 2023 Jun; 24(1):21. PubMed ID: 37337185
[TBL] [Abstract][Full Text] [Related]
57. Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity.
Andrés RM; Hald A; Johansen C; Kragballe K; Iversen L
Exp Dermatol; 2013 May; 22(5):323-8. PubMed ID: 23614738
[TBL] [Abstract][Full Text] [Related]
58. Involvement of JAK1, JAK2, and JAK3 in Stimulation of Functional Activity of Mesenchymal Progenitor Cells by Fibroblast Growth Factor.
Zyuz'kov GN; Zhdanov VV; Udut EV; Miroshnichenko LA; Simanina EV; Polyakova TY; Stavrova LA; Udut VV; Minakova MY; Dygai AM
Bull Exp Biol Med; 2016 Dec; 162(2):240-243. PubMed ID: 27905037
[TBL] [Abstract][Full Text] [Related]
59. Failure of tofacitinib to achieve an objective response in a
Wong J; Wall M; Corboy GP; Taubenheim N; Gregory GP; Opat S; Shortt J
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843425
[TBL] [Abstract][Full Text] [Related]
60. JAK1 rs310241 and JAK3 rs3008 Genotypes May Increase Susceptibility to Psoriasis: A Case Control Study.
Sayed KS; El-Komy MHM; Shehata H; ElShazly SH; El Desouky ED; Amr KS; ElAraby NM; AlOrbani AM
Skin Pharmacol Physiol; 2020; 33(4):207-212. PubMed ID: 32877908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
